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aniel Duprez, MD, PHD
inneapolis, Minnesota
oronary atherosclerotic disease is a major health-
conomical burden, and screening in asymptomatic subjects
emains a major challenge. Since the introduction of the
ramingham risk estimate, several cardiovascular risk scores
ave been developed in order to predict the coronary heart
isease (CHD) risk ranging over a 10-year period to a
ifetime span (1). Despite the improvement of this risk
ssessment, it remains still a biostatistical approach. In the
rend of personalized medicine there is a shift to detection
f markers for disease, especially in these individuals with a
ow to intermediate risk score (2).
See pages 1397 and 1407
The quantification of coronary artery calcification (CAC)
core has been studied in thousands of subjects within the
cope of primary prevention studies (3,4). With the intro-
uction of new diagnostic markers, there should be an
valuation of the following criteria: 1) the proof of concept;
) the prospective validation; 3) the incremental diagnostic
alue; 4) the clinical utility; 5) the clinical outcomes; and
) the cost-effectiveness.
The HNR (Heinz Nixdorf Recall) study (5) published in
his issue of the Journal addresses some of these matters. In
his prospective, population-based study of 4,129 subjects
ithout overt coronary artery disease at baseline with an age
ange of 45 to 75 years, traditional risk factors and CAC
core were measured. Their risk was categorized into low,
ntermediate, and high according to the Framingham risk
core and the National Cholesterol Education Program
dult Treatment Panel III (ATP III) guidelines. The study
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iews of the authors and do not necessarily represent the views of JACC or the
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erck, and Forest; and research grants from Roche and Novartis.ubjects were followed for a median time period of 5 years.
he primary end points for this study were based on
nequivocally documented incident coronary events that
et predefined study criteria. The important clinical value
f this study was that the authors used statistical methods as
he area under the receiver-operator curve or c-statistic, the
et reclassification index, and integrated discrimination
ndex to help them in their ability to reclassify the individual
isk (6).
The results demonstrated that the higher cardiovascular
isk burden was associated with higher CAC scores. A
AC score of 0 indicated an excellent prognosis. Reclassi-
cation of cardiovascular risk could significantly be im-
roved using CAC scoring. The clinical value was particu-
arly high when CAC scoring was focused on the
ntermediate-risk cohort. The shift of individuals to differ-
nt risk categories differed when using predefined CAC
hresholds within the Framingham risk score categories
ompared with the model based on Framingham variables
ith and without CAC. The results of this study demon-
trated that 30% of patients who were currently at 6% to
0% risk were reclassified. The authors’ main conclusion
as that limiting CAC score to intermediate-risk subjects
elps to correctly identify additional persons at highest risk
nd may therefore contribute to prevent coronary events in
he general population.
Another interesting question has been addressed in the
otterdam Study regarding the effect of CAC score on the
lassification of 10-year CHD risk and empirically derived
utoff values for a general elderly population (7). The major
nding of this study was that 52% of the asymptomatic
ubjects at intermediate risk were reclassified as having
ither low (30%) or high risk (22%) for CHD events.
The similarity between these studies was that the CAC
core differentiated the reclassification in the intermediate-
isk group. However, there were some differences. In the
NR study, the age range for inclusion was between 45 and
5 years; the median follow-up was 5 years; the pre-defined
AC score categories of 0, 1 to 99, 100 to 399, and 400
ere used; and 93 of the 4,129 participants eligible for
nalysis had a CHD event (nonfatal myocardial infarction
r coronary death). Their data did not support CAC scoring
n high-risk individuals. In the Rotterdam Study, the age
ange for inclusion was 55 years and older, the median
ollow-up was 9.2 years, and 135 of the 2,028 participants
ligible for analysis had a CHD event. Their empirically
erived upper cutoff values at which individuals moved from
he intermediate-risk to the high-risk or the low-risk group
ere 615 and 50 Agatston units, respectively. Their data
upported a smaller reclassification in the subjects with low
nd high Framingham risk category.
There is an overwhelming amount of published data
egarding the value of the CAC score in preventive cardio-
ascular disease screening; the large majority of these
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CAC Score and CHD Risk October 19, 2010:1415–7nd risk for CHD events in an isolated manner, without
onsidering other biomarkers (8). There are only a very
imited number of studies that examined the reclassification
f the CHD risk using the CAC score. The MESA
Multi-Ethnic Study of Atherosclerosis), a population-
ased cohort of individuals free from overt cardiovascular
isease, showed that a CAC 300 was associated with a
.67 hazard ratio for future CHD events (9). Further
nalysis of these data demonstrated that when CAC score
as added to the traditional risk factors, it resulted in a
ignificant improvement in the reclassification of CHD risk
10). The intermediate-risk group achieved a substantially
igher net reclassification index than the overall cohort.
There are still several questions to be answered before the
ractical implementation of the CAC score can be taken
nto consideration in daily clinical practice. The calcification
f the atherosclerotic plaque develops in a late stage of this
rocess. However, vulnerable plaques or coronary culprit
esions are not necessarily calcified. In a substudy of the
ORE64 (Coronary Evaluation Using Multi-Detector Spi-
al Computed Tomography Angiography Using 64 De-
ectors) multicenter trial comparing the diagnostic per-
ormance of 64-detector computed tomography with
onventional angiography, patients clinically referred for
onventional angiography were asked to undergo a calcium
core scan up to 30 days before. This study found that the
bsence of coronary calcification did not exclude obstructive
tenosis or the need for revascularization among patients
ith high enough suspicion of coronary artery disease to be
eferred for coronary angiography (11).
Studies regarding the predictive value of CAC score
re mostly focused on subjects mainly 50 years and older.
owever, the process of atherosclerotic plaque formation
n coronary arteries begins early in life (12). Moreover,
utopsy studies of young adults dying from traffic acci-
ents, homicides, and suicides have found that 60% be-
ween the ages of 30 and 39 years already have atheroscle-
otic plaque (13).
To date there are no published trials evaluating the
mpact of specific therapy on clinical outcome in asymp-
omatic subjects identified as having only noncalcified ath-
roma by computed tomography angiography. Another
itfall of CAC score is the effect of preventive therapy on
he progression of CAC score. In 2 randomized, double-
lind trials, the effect of statins were studied on the
rogression of CAC score. Over a period of 12 months,
ntensive atorvastatin therapy was unable to attenuate CAC
rogression compared with standard atorvastatin therapy
14). Similar findings were found with high-dose simvasta-
in therapy versus placebo.
There was an increase of 9% of CAC score after 12
onths for 80 mg of simvastatin versus 5% in the placebo
roup. There is no doubt that statin therapy reduces CHD
orbidity and mortality.Future research regarding the utilization of CAC score in
aily clinical practice is warranted. Information is needed
rom a prospective risk modification trial in asymptomatic
ubjects at high risk but with low CAC scores. A health-
conomical project would be very interesting to examine
hether the determination of CAC score is cost-effective in
symptomatic people. CAC score has to add value over risk
actor scoring by providing additional information to change
reatment, and hence cardiac outcome, at an affordable cost
er quality-adjusted life-year (16).
A frequent question is when ideally a repeat CAC score
hould be considered when the initial CAC score is 0 or
ow. Such a determination will help establish a standard of
are and will cut down the costs associated with frequent
canning. Recently Min et al. (17) found that repeat CAC
coring should not be performed for a minimum of 4 years
n individuals with a baseline CAC score of 0. Their data
uggested that the rates of progression of CAC are not
inear.
In the present study, the degree of baseline CAC score was
he most important determinant for rates of CAC progression.
he clinical message is that a 1-time CAC score may be
isleading, especially with a 0 or low CAC score. If the utility
f CAC screening is to be tested in clinical trials, it will be
mportant to define the natural history of progression to
etermine whether serial screening can enhance prediction
f incident risk of myocardial events, and if so, to determine
he appropriate screening interval.
In conclusion, noninvasive assessment of atherosclerosis
sing CAC score is regarded as most useful in asymptom-
tic subjects classified in intermediate Framingham risk
ange in which treatment decisions are often uncertain.
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